The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis.
Jakub P HlávkaSoeren MattkeAsa WilksPublished in: Applied health economics and health policy (2021)
A DPM may result in faster access to CHF gene therapy and may thus reduce hospital admissions and mortality in contrast to a status quo payment with the same budget constraint. Although the financial benefits of a DPM in CHF gene therapy are limited, it is possible that deferred payments will show greater promise for treatments with higher cost offsets.
Keyphrases
- gene therapy
- heart failure
- affordable care act
- health insurance
- magnetic resonance
- cardiovascular events
- genome wide
- copy number
- big data
- risk factors
- type diabetes
- atrial fibrillation
- machine learning
- contrast enhanced
- risk assessment
- coronary artery disease
- deep learning
- artificial intelligence
- genome wide analysis